Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Liver
100%
Chemotype
100%
Plasmodium Falciparum
100%
PfPKG Inhibitor
100%
Sporozoite
100%
Plasmodium Infection
100%
Protein Kinase
50%
Prediction Accuracy
50%
Further Development
50%
Malaria
50%
Free Energy
50%
Orally Bioavailable
50%
Cyclic GMP
50%
Chloroquine
50%
Selectivity Profile
50%
Pyrimethamine
50%
Cycloguanil
50%
Climate-driven
50%
In Silico Modeling
50%
Insecticide
50%
Preclinical Development
50%
Energy Modeling
50%
Infection Prevention
50%
P. Berghei
50%
Global Health Challenges
50%
Antimalarial Activity
50%
Field Isolates
50%
P. Cynomolgi
50%
Compound Design
50%
Structural Modeling
50%
Cross-resistance
50%
Chemoprevention
50%
Emerging Resistance
50%
Liver Infection
50%
Hypnozoite
50%
Chemoprotective Effect
50%
Single Oral Dose
50%
Off-target Effects
50%
Once-weekly
50%
Mefloquine
50%
Sulfadoxine
50%
Pharmacokinetic Modeling
50%
Immunology and Microbiology
Chemotype
100%
Infectious Disease
100%
Plasmodium
100%
Sporozoite
100%
Infection
100%
Plasmodium falciparum
50%
Pharmacokinetics
50%
Chloroquine
50%
Pyrimethamine
50%
Phosphotransferase
50%
Malaria
50%
Kinase
50%
Global Health
50%
Cross-Resistance
50%
Preclinical Study
50%
Mefloquine
50%
Medicine and Dentistry
Infection
100%
Plasmodium
100%
Antimalarial
100%
In Silico
50%
Pyrimethamine
50%
Oral
50%
Global Health
50%
Mefloquine
50%
Cycloguanil
50%
Cyclic GMP Dependent Protein Kinase
50%
Chemoprophylaxis
50%
Plasmodium falciparum
50%
Malaria
50%
Pharmacokinetic
50%
Cross Resistance
50%
Chloroquine
50%
Kinase
50%
Sulfadoxine
50%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
100%
Plasmodium
100%
Antimalarial Agent
100%
Sporozoite
100%
Plasmodium falciparum
50%
Chloroquine
50%
Pyrimethamine
50%
Cycloguanil
50%
Cyclic GMP Dependent Protein Kinase
50%
Malaria
50%
Cross-Resistance
50%
Target Activity
50%
Pharmacokinetic Modeling
50%
Sulfadoxine
50%
Mefloquine
50%